Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and ge...
Guardado en:
Autores principales: | Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: David Ternant, et al.
Publicado: (2021) -
Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review
por: Laila Aldars-García, et al.
Publicado: (2021) -
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
por: Luis G. Guijarro, et al.
Publicado: (2021) -
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
por: Byron P. Vaughn
Publicado: (2021) -
Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
por: Cao Y, et al.
Publicado: (2021)